个性化文献订阅>期刊> Journal of clinical investigation
 

EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors

  作者 White, RE; Ramer, PC; Naresh, KN; Meixlsperger, S; Pinaud, L; Rooney, C; Savoldo, B; Coutinho, R; Bodor, C; Gribben, J; Ibrahim, HA; Bower, M; Nourse, JP; Gandhi, MK; Middeldorp, J; Cader, FZ; Murray, P; Munz, C; Allday, MJ  
  选自 期刊  Journal of clinical investigation;  卷期  2012年122-4;  页码  1487-1502  
  关联知识点  
 

[摘要]Epstein-Barr virus (EBV) persistently infects more than 90% of the human population and is etiologically linked to several B cell malignancies, including Burkitt lymphoma (BL), Hodgkin lymphoma (HL), and diffuse large B cell lymphoma (DLBCL). Despite its growth transforming properties, most immune-competent individuals control EBV infection throughout their lives. EBV encodes various oncogenes, and of the 6 latency-associated EBV-encoded nuclear antigens, only EBNA3B is completely dispensable for B cell transformation in vitro. Here, we report that infection with EBV lacking EBNA3B leads to aggressive, immune-evading monomorphic DLBCL-like tumors in NOD/SCID/gamma(-/-)(c) mice with reconstituted human immune system components. Infection with EBNA3B-knockout EBV (EBNA3BKO) induced expansion of EBV-specific T cells that failed to infiltrate the tumors. EBNA3BKO-infected B cells expanded more rapidly and secreted less T cell-chemoattractant CXCL10, reducing T cell recruitment in vitro and T cell-mediated killing in vivo. B cell lines from 2 EBV-positive human lymphomas encoding truncated EBNA3B exhibited gene expression profiles and phenotypic characteristics similar to those of tumor-derived lines from the humanized mice, including reduced CXCL10 secretion. Screening EBV-positive DLBCL, HL, and BL human samples identified additional EBNA3B mutations. Thus, EBNA3B is a virus-encoded tumor suppressor whose inactivation promotes immune evasion and virus-driven lymphomagenesis.

 
      被申请数(0)  
 

[全文传递流程]

一般上传文献全文的时限在1个工作日内